Breaking News

IBT, Emergent BioSolutions in R&D Vax Pact

Emergent gains exclusive rights to IBT's vaccine antigens to develop and manufacture Filovirus vaccine

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Integrated BioTherapeutics (IBT) has entered into an exclusive worldwide license agreement with Emergent BioSolutions under which Emergent will gain exclusive rights to use IBT’s vaccine antigens and know-how in a joint research, development, and manufacturing collaboration focused on an equine-based hyperimmunoglobulin for the treatment of hemorrhagic fever caused by Filoviruses. Financial terms were not disclosed. Filoviruses, including Ebola, Sudan, Bundibugyo, and Marburg viruses, cau...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters